|04/24/19||ChromaDex Furthers TRU NIAGEN® Global Expansion in Canada with WELL Health Technologies|
|Distribution agreement for Tru Niagen (nicotinamide riboside) in Vancouver area provides access to high-end pharmacies and clinics
LOS ANGELES, April 24, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today a new distribution partnership for TRU NIAGEN® with Vancouver-based WELL Health Technologies Corp. (TSX.V: WELL) who intends on distributing TRU NIAGEN® via its partner network of pharmacy and other allied health businesses.
According to Orbis Research, the $250 billio... |
|04/15/19||ChromaDex Drives Global Expansion Strategy for TRU NIAGEN® with Specialty Retail Launch and Expanded eCommerce Distribution in Canada|
|ChromaDex flagship Tru Niagen (nicotinamide riboside) product now available in Showcase specialty retail stores in Canada
LOS ANGELES, April 15, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today the latest milestone in its global expansion strategy for TRU NIAGEN®, with a strategic deal with specialty retailer Showcase in Toronto, Canada. Tru Niagen is now available in 36 Showcase stores in the greater Toronto area as well as Showcase’s online store. Showcase operates 118... |
|04/09/19||New Study Deepens Research Into the Potential Cardiovascular Health Benefits of Supplementation with Nicotinamide Riboside (NR)|
|Data published in the Journal of American College of Cardiology
shows that this novel form of vitamin B3 helps maintain mitochondrial
function in an animal model by stimulating a cellular repair pathway;
preliminary human data also support future testing of NR in connection
with cardiac health
LOS ANGELES--(BUSINESS WIRE)--Apr. 9, 2019--
Corp. (NASDAQ:CDXC) today reported that results of a new preclinical
study showed that sup... |
|04/03/19||Dr. Charles Brenner, Discoverer of Nutrient Nicotinamide Riboside as a Vitamin, Announced as Speaker at Upgrade XP’s Sixth Annual Biohacking Conference|
|World’s leading expert on NAD metabolism to speak at #UpgradeXP2019
LOS ANGELES, April 03, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today its Chief Scientific Advisor, Dr. Charles Brenner, the world’s foremost authority on NAD metabolism and discoverer of nicotinamide riboside as a vitamin, will speak at the Sixth Annual Biohacking Conference, a three-day immersive experience for the human performance industry. Hosted by Upgrade Labs, the conference runs Friday, April... |
|03/11/19||ChromaDex to Present at the 31st Annual ROTH Conference|
|LOS ANGELES, March 11, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today that its Chief Executive Officer, Rob Fried, Chairman and Co-Founder, Frank Jaksch, and Chief Financial Officer, Kevin Farr, will present at the 31st annual ROTH Capital Partners Conference at the Ritz-Carlton in Dana Point, CA.
The ChromaDex management team is scheduled to present on Monday, March 18, at 3:30 p.m. Pacific Time. ChromaDex management will also attend one-on-one meetings with instit... |
|03/08/19||ChromaDex Brings TRU NIAGEN® to SXSW® 2019|
|TRU NIAGEN® milestones to be highlighted at South by Southwest® SXSW® gathering of global professionals
LOS ANGELES, March 08, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today it will feature its cellular health product, TRU NIAGEN®, at SXSW®, as it marks the achievement of attaining over 160 research collaborations around the world on its patented NIAGEN® (nicotinamide riboside) ingredient.
"To help SXSW® attendees who need an extra boost in their busy lives, we'll b... |
|03/07/19||ChromaDex Corporation Reports 2018 Financial Results|
|- Full Year 2018 Net Revenues Increased by 49% to $31.6 Million and Fourth Quarter 2018 Net Revenues Increased by 20% to $9.1 Million -
Fourth Quarter 2018 Highlights vs. Fourth Quarter 2017
Entered into a global license and supply agreement with Nestlé Health Science (“NHSc”), which provides NHSc with the exclusive right to include TRU NIAGEN® in its branded medical nutrition products and co-exclusive rights to include TRU NIAGEN in its protein based ready to drink or loose powder bever... |
|03/01/19||ChromaDex to Present at the 39th Annual Cowen Health Care Conference|
|LOS ANGELES, March 01, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will present at the 39th Annual Cowen Heath Care Conference at the Boston Marriott Copley Place in Boston, MA.
The ChromaDex management team is scheduled to present on Monday, March 11, at 4:50 p.m. ET. ChromaDex management will also attend one-on-one meetings with institutional investors throughout the day.
The ... |
|02/28/19||ChromaDex to Report Fourth Quarter 2018 Financial Results on Thursday, March 7, 2019|
|LOS ANGELES, Feb. 28, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs., Mar. 7, 2019 at 4:30 p.m. Eastern time to discuss its financial results for the fourth quarter ended December 31, 2018. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.
Investor Conference Call:
ChromaDex management will host an investor conference call to ... |
|01/23/19||New Study Shows Supplementation with Nicotinamide Riboside (NR) During Breastfeeding Yields Measurable, Lasting Benefits to Mothers and Offspring in Animal Model|
|Landmark preclinical lactation study of unique form of vitamin B3 (nicotinamide riboside) showing remarkable results in rodents published in Cell Reports
LOS ANGELES, Jan. 23, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) today reported that results of a first-of-a-kind preclinical study on lactation have shown that supplementation with the unique B3 vitamin nicotinamide riboside (NR, or Niagen) confers significant and enduring physiological benefits to mothers and offspring. Conduct... |
|01/22/19||ChromaDex Prepared to Proceed with Patent Infringement Action Against Elysium Health|
|ChromaDex to move forward with patent infringement action, following unsuccessful challenge by Elysium Health during Inter Partes Review (IPR)
LOS ANGELES, Jan. 22, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) today reported the rejection of Elysium Health Inc.’s challenge to Claim 2 of U.S. Patent No. 8,383,086 ("the '086 patent") by the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office. ChromaDex reported on January 22, 2018 that the PTAB denied Elysium... |